Charles Wilmer, MD
Interventional Cardiology · Atlanta, GANPI 1942205224
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,700 of the $36,705 with a category attached, or 78.2%. Johnson & Johnson accounts for 78.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $31,673 and has fallen 99.0% since, to $320 in 2025.
Across 125 payments — averaging $293.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$29K
- E.r. Squibb & Sons, L.L.C.$7K
- Novartis$530
- Inspire Medical Systems, Inc.$168
- Pfizer$96
- Novo Nordisk$61
- plus $185 from 6 others
Across 2 payments — averaging $6.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$12
What the payments were for
- Consulting fees$5501%
- Speaking & faculty fees$28,70078%
- Travel & lodging$5,39815%
- Food & beverage$1,9765%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 52 | $28,766 |
| E.r. Squibb & Sons, L.L.C. | 16 | $6,900 |
| Novartis | 36 | $530 |
| Inspire Medical Systems, Inc. | 2 | $168 |
| Pfizer | 5 | $96 |
| Novo Nordisk | 4 | $61 |
| Amgen | 3 | $48 |
| AstraZeneca | 2 | $39 |
| Angiodynamics, Inc. | 1 | $32 |
| Boehringer Ingelheim | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,705 in reported general payments places this provider in the 80th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 342 | $430,245 |
| XareltoRivaroxaban | 182 | $241,155 |
| JardianceEmpagliflozin | 30 | $44,351 |
| EntrestoSacubitril/Valsartan | 25 | $29,421 |
| Ezetimibe | 538 | $14,497 |
| Rosuvastatin Calcium | 1,125 | $13,830 |
| Flecainide Acetate | 180 | $11,432 |
| VascepaIcosapent Ethyl | 26 | $9,795 |
| Atorvastatin Calcium | 809 | $6,785 |
| Amlodipine Besylate | 837 | $5,514 |
| Dofetilide | 15 | $5,254 |
| Metoprolol Succinate | 380 | $5,072 |
| Losartan Potassium | 416 | $4,456 |
| Metoprolol Tartrate | 673 | $3,881 |
| Nebivolol Hcl | 49 | $3,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $96 | $430,245342 claims |
| Johnson & JohnsonXarelto | $28,766 | $241,155182 claims |
| Boehringer IngelheimJardiance | $29 | $44,35130 claims |
| NovartisEntresto | $530 | $29,42125 claims |
| AstraZenecaCrestor | $39 | $3,50313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Atlanta
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Katherine KunkelAtlanta$189K
- James StewartAtlanta$174K
- Pratik SandesaraAtlanta$165K
- Chandanreddy DevireddyAtlanta$121K
- Prashant KaulAtlanta$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.